The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.

DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong preliminary fourth-quarter ...

Dexcom is already working on its G8 sensor for continuous glucose monitoring (CGM). But before you get too excited, the product is still a couple of years out, CEO Jake Leach told MD+DI during the J.P ...

For DexCom, Barclays pointed to Abbott steadily taking market share over recent years, first in non-insulin-intensive Type 2 diabetes and increasingly in insulin-intensive Type 1 and Type 2 patients.

Today, I'm going to talk about clinical concerns that I think both our patients and we have been having about sensors. First of all, there was a recall of some of the Freestyle Libre 3 Plus devices, ...

When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

DexCom, Inc.’s (NASDAQ:DXCM) third-quarter 2025 revenue reached $1.209 billion, beating the analyst consensus estimate of $1.179 billion. Revenue grew 22% year-over-year on a reported basis and 20% ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

Goldman Sachs initiated coverage on Insulet Corporation (NASDAQ:PODD), citing the company to benefit from accelerating the adoption of patch pump technology as it is the only participant in the ...

May 1 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat first-quarter sales estimates helped by strong demand for its continuous glucose monitors (CGMs) used by patients with ...